ResourcesNot an actual patient
Patient Support Program
The INBRACE® Support Program offers support designed to help patients who are prescribed INGREZZA® (valbenazine) capsules
From financial assistance to prescription fulfillment and product support, the program assists your patients and their caregivers—so they can focus on treatment goals.
Accessible and affordable for your patients
There are a variety of financial assistance programs to help your patients fill their prescriptions for INGREZZA.
- INGREZZA has broad Medicare Part D coverage
- Most patients pay less than $10 in out-of-pocket cost for INGREZZA
Eligible patients may qualify for a $0 copay on their INGREZZA prescriptiona
Access the INGREZZA Savings Program
You can also call 84-INGREZZA
(844-647-3992), 8 am – 8 pm ET, M – F
- aThis offer is valid only for patients who have commercial (nongovernment-funded) insurance. Additional terms and conditions apply.
Downloadable resources for you and your patients
INGREZZA mechanism of action
INDICATION & USAGE
INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.
IMPORTANT SAFETY INFORMATION
INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.
WARNINGS & PRECAUTIONS
INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.
INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.
INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.
The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see INGREZZA full Prescribing Information